Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Notable Labs (NTBL)
NASDAQ:NTBL
Notable Labs (NTBL) Stock Price & Analysis
747 Followers
NTBL Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.51 - $10.78
Previous Close$0.58
Volume76.83K
Average Volume (3M)454.95K
Market Cap
$5.62M
Enterprise Value-$656.12K
Total Cash (Recent Filing)$8.20M
Total Debt (Recent Filing)$1.92M
Price to Earnings (P/E)―
Beta1.55
Next Earnings
Aug 12, 2024EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.21
Shares Outstanding9,018,261
10 Day Avg. Volume71,281
30 Day Avg. Volume454,949
Standard Deviation0.24
R-Squared0.05
Alpha-0.03
Financial Highlights & Ratios
Price to Book (P/B)0.41
Price to Sales (P/S)20.18
Price to Cash Flow (P/CF)-0.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-2.11
Enterprise Value/Gross Profit-5.81
Enterprise Value/Ebitda0.20
Forecast
1Y Price Target
$5.00Price Target Upside700.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Notable Labs News
PremiumCompany Announcements
Notable Labs Unveils Strategic Outlook in Business Update
Bulls Say, Bears Say
Bulls Say
Clinical TrialsNotable's lead program, volasertib, has shown clinical activity across liquid and solid tumors in phase I/II/III studies.
Diagnostic AdvancementAt AACR, the company presented a companion diagnostic to predict volasertib responders, enhancing the trial's potential success.
Research PresentationThe company recently presented two posters related to its PPMP platform at the American Association for Cancer Research Annual Meeting 2024 (AACR 2024).
Bears Say
Drug DevelopmentFosciclopirox did not produce any responses in nine evaluable AML patients, which darkens the outlook for the drug in AML treatment.
EarningsAnalyst lowers 12-month price target to $7, reflecting a higher projected future share count and expected dilution from future capital raises.
Platform EfficacyThe absence of responders in the trial did not allow Notable Labs to demonstrate the capability of PPMP to predict positive responses.
---
Ownership Overview
71.74% Insiders
0.01% Mutual Funds
2.12% Other Institutional Investors
26.13% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
NTBL FAQ
What was Notable Labs’s price range in the past 12 months?
Notable Labs lowest stock price was $0.51 and its highest was $10.78 in the past 12 months.
What is Notable Labs’s market cap?
Currently, no data Available
When is Notable Labs’s upcoming earnings report date?
Notable Labs’s upcoming earnings report date is Aug 12, 2024 which is in 16 days.
How were Notable Labs’s earnings last quarter?
Currently, no data Available
Is Notable Labs overvalued?
According to Wall Street analysts Notable Labs’s price is currently Undervalued.
Does Notable Labs pay dividends?
Notable Labs does not currently pay dividends.
What is Notable Labs’s EPS estimate?
Notable Labs’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Notable Labs have?
Notable Labs has 9,674,496 shares outstanding.
What happened to Notable Labs’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Notable Labs?
Among the largest hedge funds holding Notable Labs’s share is ARK Investment Management LLC. It holds Notable Labs’s shares valued at N/A.
---
Notable Labs Stock Smart Score
Company Description
Notable Labs
Vascular Biogenics Ltd. is in the clinical-stage biopharmaceutical company, which engages in the discovery, development and commercialization of first-in-class treatments for cancer. It offers different programs for cancer and inflammatory disease patients such as vascular targeting system and Lecinoxoids. The company was founded by Dror Harats and Jacob George on January 27, 2000 and is headquartered in Modi'in, Israel.
---
NTBL Stock 12 Month Forecast
Average Price Target
$5.00
▲(700.00% Upside)
Technical Analysis
Best Analysts Covering NTBL
1 Year
1 Year Success Rate
0/4 ratings generated profit
1 Year Average Return
-57.40%
reiterated a buy rating 3 months ago
Copying Silvan Tuerkcan's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -57.40% per trade.
---